Fig. 1: TLR-induced NF-κB activation is repressed in cells expressing the MYD88 S257A mutant. | Blood Cancer Journal

Fig. 1: TLR-induced NF-κB activation is repressed in cells expressing the MYD88 S257A mutant.

From: The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain

Fig. 1

A A schematic diagram of wild-type and mutant MYD88 proteins. Amino acid positions are shown according to protein accession NCBI NP_002459.2. B Immunoblot analysis of MYD88 in U2932 and RIVA transduced lentiCas9-Blast and subsequently transfected with pLentiGuide-GFP containing two different single guide RNAs (sgRNA) targeting MYD88. Cells were allowed to recover for 48 h after transfection before the GFP positive cells were sorted. β-tubulin was used as loading control. C Immunoblot analysis of phosphorylated p65 (Ser536) and MYD88 in U2932 and RIVA expressing MYD88 WT or MYD88 S257A. Cells were serum starved for 1 h at 37 °C before stimulation for 15 min with 500 ng/ml CpG. Total p65 and β-tubulin were used as loading controls. D Immunoblot analysis of phosphorylated p65 (Ser536) and MYD88 in U2932 expressing MYD88 WT or MYD88 S257A. Cells were serum starved for 1 h at 37 °C before stimulation for 5, 15, 30 or 60 min with 500 ng/ml CpG. Total p65, β-actin and β-tubulin were used as loading controls.

Back to article page